Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated November 7, 2024, discloses insider trading activity in compliance with Article 19 of Regulation No. 596/2014 on market abuse. The report details transactions executed by board members, executives, and associated persons. Novo Nordisk is a global healthcare company headquartered in Denmark, employing approximately 69,000 people across 80 countries.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure of a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Purchase of ADRs |
| Volume | 1,400 ADRs |
| Price per ADR | DKK 697.24 |
| Total Value | DKK 1,054,226.88 |
| Transaction Date | November 6, 2024 |
| Exchange | New York Stock Exchange |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely reports a single purchase transaction by a Board member.
Guidance, Outlook, and Risks
The document contains no management guidance, future outlook, risk factors, or discussion of contingencies. It serves only to notify the market of the specific insider transaction described above.
Key Facts for Investor Verification
- Insider Identity: The transaction was executed by Choi Lai Christina Law, a Member of the Board of Directors.
- Transaction Nature: This was an initial notification of a purchase, not a sale.
- Instrument: The trade involved American Depositary Receipts (ADRs) identified by the code NVO.
- Regulatory Basis: The disclosure is mandated by EU market abuse regulations (Regulation No. 596/2014) and filed with the SEC as a foreign private issuer.